Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.

P J Brown1, L W Stuart, K P Hurley

  • 1GlaxoSmithKline, Research Triangle Park, NC 27709-3398, USA. pjb5890@gsk.com

Bioorganic & Medicinal Chemistry Letters
|May 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spina Bifida Successfully Treated by Ligature and Puncture.

Atlanta medical and surgical journal·2022
Same author

Use of a novel oleaginous microorganism as a potential source of lipids for weanling pigs<sup></sup>.

Translational animal science·2020
Same author

Genome-wide meta-analysis of variant-by-diuretic interactions as modulators of lipid traits in persons of European and African ancestry.

The pharmacogenomics journal·2019
Same author

Cardiac Leiomyosarcoma in a Cat Presenting for Bilateral Renal Neoplasia.

Journal of comparative pathology·2019
Same author

Report of Obstetric Cases Occurring in Hospital Practice.

Glasgow medical journal·2018
Same author

Two Cases of Concealed Accidental Hæmorrhage at the Full Term of Utero-Gestation.

Glasgow medical journal·2018
Same journal

Identification of TYK2 activators. Part 2: Optimization of terminal alkyne substituents to enhance activation potency.

Bioorganic & medicinal chemistry letters·2026
Same journal

Synthesis and biological investigation of phenothiazine-based derivatives as potential HDAC6 inhibitors for treatment of glioblastoma multiforme.

Bioorganic & medicinal chemistry letters·2026
Same journal

Solid-phase synthesis and antimicrobial activities of lipid-neomycin conjugates.

Bioorganic & medicinal chemistry letters·2026
Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026
See all related articles

Researchers synthesized novel urea-substituted thioisobutyric acids. GW7647 was identified as a potent and selective human PPARalpha agonist with significant lipid-lowering effects in animal models.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate gene expression involved in metabolism.
  • Dyslipidemia is a major risk factor for cardiovascular disease, and PPARs are key targets for therapeutic intervention.

Purpose of the Study:

  • To synthesize and evaluate novel urea-substituted thioisobutyric acids as potential modulators of human PPAR subtypes.
  • To identify potent and selective agonists for PPARalpha with therapeutic potential for dyslipidemia.

Main Methods:

  • Solid-phase, parallel-array synthesis was employed to generate a library of compounds.
  • In vitro assays were performed to determine the activity and selectivity of synthesized compounds against human PPARalpha, PPARgamma, and PPARdelta.

Related Experiment Videos

  • In vivo studies in animal models of dyslipidemia were conducted to assess lipid-lowering efficacy.

    • Main Results:

    • GW7647 (compound 3) was identified as a highly potent human PPARalpha agonist.
    • GW7647 demonstrated approximately 200-fold selectivity for PPARalpha over PPARgamma and PPARdelta.
    • GW7647 exhibited potent lipid-lowering activity in animal models of dyslipidemia.

    Conclusions:

    • GW7647 is a potent and selective human PPARalpha agonist.
    • GW7647 represents a valuable chemical tool for investigating PPARalpha biology in human cells and disease models.
    • The findings support the therapeutic potential of PPARalpha agonists in treating dyslipidemia.